CA
NZ
UK
AU
IND
US
…
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2011-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2011-10-31 |
| Income before tax | -61.38M | -73.43M | -36.94M | -20.74M | - |
| Net income | -60.81M | -73.52M | -37.08M | -21.17M | - |
| Selling general administrative | 26.82M | 17.89M | 9.98M | 8.92M | 2.52M |
| Selling and marketing expenses | 14.99M | 11.81M | 5.96M | 4.05M | - |
| Gross profit | -8.54M | -7.74M | -8.07M | -0.23M | - |
| Reconciled depreciation | 2.84M | 1.53M | 1.51M | 1.46M | - |
| Ebit | -66.06M | -47.23M | -30.54M | -18.63M | - |
| Ebitda | -63.22M | -46.51M | -29.01M | -17.16M | - |
| Depreciation and amortization | 2.84M | 0.72M | 1.53M | 1.48M | - |
| Operating income | -63.22M | -47.23M | -30.54M | -18.63M | - |
| Other operating expenses | 80.35M | 70.46M | 46.62M | 35.15M | - |
| Interest expense | 1.78M | 2.65M | 3.45M | 2.38M | 0.00M |
| Tax provision | -0.58M | 0.09M | 0.13M | 0.43M | - |
| Net interest income | 1.78M | -2.65M | -3.45M | -2.38M | - |
| Income tax expense | -0.58M | 0.09M | 0.13M | 0.43M | - |
| Total revenue | 17.13M | 23.23M | 16.08M | 16.51M | 10.97M |
| Total operating expenses | 54.68M | 39.49M | 22.47M | 18.40M | - |
| Cost of revenue | 25.67M | 30.97M | 24.15M | 16.75M | 11.78M |
| Total other income expense net | 1.84M | -26.20M | -6.40M | -2.11M | - |
| Net income from continuing ops | -60.81M | -73.52M | -37.08M | -21.17M | - |
| Net income applicable to common shares | -60.81M | -78.03M | -37.01M | -24.83M | - |
| Breakdown | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 |
| Total assets | 143.45M | 190.65M | 241.17M | 70.00M | 31.69M |
| Other current assets | 2.82M | 0.70M | 3.95M | 0.84M | 0.34M |
| Total liab | 25.46M | 26.48M | 20.19M | 45.18M | 32.41M |
| Total stockholder equity | 117.99M | 164.17M | 220.98M | 24.82M | -0.72M |
| Other current liab | 9.91M | 8.15M | 0.34M | 0.11M | 0.08M |
| Common stock | 0.42M | 0.42M | 0.41M | 0.01M | 0.00M |
| Capital stock | 0.42M | 0.42M | 0.41M | 151.83M | 81.85M |
| Retained earnings | -428.38M | -375.92M | -315.11M | -241.59M | -204.51M |
| Other liab | - | 0.23M | 2.02M | 0.70M | 0.68M |
| Other assets | 0.00M | 0.00M | 1.77M | 0.80M | 0.48M |
| Cash | 24.29M | 27.06M | 178.39M | 30.08M | 12.46M |
| Total current liabilities | 18.99M | 19.05M | 18.17M | 15.54M | 10.53M |
| Current deferred revenue | 5.97M | 4.71M | 3.31M | 4.42M | 1.88M |
| Net debt | -16.94M | -19.10M | -178.39M | -5.27M | 5.35M |
| Short term debt | 1.13M | 0.77M | 10.58M | 6.54M | 5.35M |
| Short long term debt total | 7.35M | 7.97M | - | 24.81M | 17.81M |
| Other stockholder equity | 546.05M | 540.77M | 294.52M | 114.58M | 121.93M |
| Property plant equipment | - | 20.88M | 11.30M | 7.05M | 7.59M |
| Total current assets | 120.42M | 138.58M | 218.12M | 62.15M | 23.61M |
| Long term investments | 2.91M | 29.79M | 9.97M | - | - |
| Net tangible assets | - | 162.77M | 220.98M | -121.33M | -79.59M |
| Short term investments | 67.77M | 81.58M | 15.11M | 15.00M | 0.00M |
| Net receivables | 5.58M | 5.37M | 5.00M | 5.78M | 4.92M |
| Long term debt | - | - | - | 24.81M | 17.81M |
| Inventory | 19.96M | 21.19M | 15.67M | 8.96M | 5.75M |
| Accounts payable | 1.97M | 5.43M | 3.94M | 4.47M | 3.21M |
| Accumulated other comprehensive income | -0.10M | -1.11M | -0.02M | 0.00M | - |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Non currrent assets other | 0.77M | 1.40M | 1.77M | 0.80M | 0.48M |
| Non current assets total | 23.04M | 52.07M | 23.05M | 7.85M | 8.08M |
| Capital lease obligations | 7.35M | 7.97M | - | - | - |
| Breakdown | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2011-10-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2011-10-31 |
| Investments | -93.47M | -10.09M | -14.98M | -14.98M | - |
| Change to liabilities | 2.88M | -1.64M | 3.52M | 2.43M | 0.70M |
| Total cashflows from investing activities | -93.47M | -13.29M | -15.67M | -1.70M | - |
| Net borrowings | -0.03M | -26.17M | 16.50M | 16.50M | - |
| Total cash from financing activities | 0.69M | 216.75M | 64.23M | 14.87M | 2.99M |
| Change to operating activities | -2.00M | 0.43M | 0.11M | -0.10M | - |
| Net income | -60.81M | -73.52M | -37.08M | -21.17M | - |
| Change in cash | -151.32M | 148.49M | 17.57M | -7.97M | - |
| Begin period cash flow | 178.67M | 30.18M | 12.61M | 20.58M | - |
| End period cash flow | 27.35M | 178.67M | 30.18M | 12.61M | 20.58M |
| Total cash from operating activities | -58.55M | -54.96M | -31.00M | -21.15M | - |
| Issuance of capital stock | 0.00M | 243.86M | 49.94M | 14.86M | - |
| Depreciation | 2.84M | 1.53M | 1.51M | 1.46M | - |
| Dividends paid | -0.57M | - | - | - | - |
| Change to inventory | -5.84M | -6.77M | -3.37M | -3.92M | - |
| Change to account receivables | -0.36M | -0.02M | -1.36M | -0.51M | - |
| Sale purchase of stock | 0.16M | - | - | - | - |
| Other cashflows from financing activities | 0.57M | 78.80M | 82.16M | 14.86M | - |
| Change to netincome | 4.75M | 25.03M | 5.67M | 0.67M | - |
| Capital expenditures | 6.74M | 3.22M | 0.69M | 1.70M | 0.00M |
| Change in working capital | -5.33M | -8.00M | -1.10M | -2.11M | - |
| Stock based compensation | 4.02M | 1.84M | 0.53M | 0.47M | - |
| Other non cash items | 0.73M | 0.40M | 2.01M | 0.45M | - |
| Free cash flow | -65.29M | -58.18M | -31.69M | -22.84M | - |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| RPID Rapid Micro Biosystems Inc |
-0.05 6.73% |
0.74 | - | - | 1.80 | 0.34 | 0.12 | 0.82 |
| ABT Abbott Laboratories |
1.63 1.56% |
106.20 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-0.57 0.59% |
96.54 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-19.89 6.38% |
291.86 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.11 0.22% |
47.69 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
1001 Pawtucket Boulevard West, Lowell, MA, United States, 01854
978 349 3200
193
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert G. Spignesi Jr. | CEO, Pres & Director | 1970 |
| Mr. Sean M. Wirtjes | CFO, Treasure & Sec. | 1969 |
| Mr. John J. Addington Wilson | Chief Operating Officer | 1968 |
| Michael Beaulieu C.F.A. | VP of Investor Relations & Corp. Communications | NA |
| Mr. Jonathan Paris | Sr. VP, Gen. Counsel & Sec. | 1976 |
| Ms. Victoria Vezina | Chief HR Officer | 1968 |
| Mr. Robert G. Spignesi Jr. | CEO, President & Director | 1970 |
| Mr. Sean M. Wirtjes | Chief Financial Officer | 1969 |
| Michael Beaulieu C.F.A. | Vice President of Investor Relations & Corporate Communications | NA |
| Mr. Michael Wysocki | Senior Vice President of Sales & Marketing | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
-1.82%
Communication Services
-0.22%
Consumer Cyclical
-0.13%
Consumer Defensive
+0.32%
Energy
+0.15%
Financial Services
-0.85%
Financials
+2.34%
Healthcare
-1.28%
Industrials
-0.96%
Real Estate
-0.38%
Technology
-2.73%
Utilities
-0.31%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...